

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA474)**

## **NICE GUIDANCE ISSUED SEPTEMBER 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 0616 – March 2016**

**Sorafenib (Nexavar<sup>®</sup>) 200 mg film-coated tablets**

**Submission by Bayer Healthcare Pharmaceuticals**

#### **Recommendation of AWMSG**

**Sorafenib (Nexavar<sup>®</sup>) is recommended for restricted use within NHS Wales in the following circumstances for the treatment of hepatocellular carcinoma:**

- **patients with advanced hepatocellular carcinoma for whom surgical or loco-regional therapies have failed or were not suitable.**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.**

**Sorafenib (Nexavar<sup>®</sup>) is not recommended for use within NHS Wales outside of these circumstances.**

#### **Additional note(s):**

- AWMSG acknowledged that the criteria for appraising life-extending, end-of-life medicines applied to sorafenib (Nexavar<sup>®</sup>) for the indication under consideration.
- AWMSG considered that sorafenib (Nexavar<sup>®</sup>) satisfies the criteria for appraisal under orphan status.
- The evidence provided only supports its use in patients with an Eastern Cooperative Oncology Group (ECOG) or World Health Organisation (WHO) performance status of 0–2.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 284), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0616:  
Sorafenib (Nexavar®). Reference number 284. March 2016